Therapeutic effects of composite probiotics derived from fermented camel milk on metabolic dysregulation and intestinal barrier integrity in type 2 diabetes rats
BackgroundIn the Kazakh community of Xinjiang, China, fermented camel milk has been traditionally used to manage diabetes. This study evaluates the effects of composite probiotics derived from fermented camel milk (CPCM) on metabolic disturbances in a rat model of Type 2 diabetes (T2DM).MethodsT2DM...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2024.1520158/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841556715395350528 |
|---|---|
| author | Tabusi Manaer Tabusi Manaer Tabusi Manaer Tabusi Manaer Jialehasibieke Sailike Xin Sun Baheban Yeerjiang Baheban Yeerjiang Baheban Yeerjiang Baheban Yeerjiang Xinhua Nabi Xinhua Nabi Xinhua Nabi Xinhua Nabi |
| author_facet | Tabusi Manaer Tabusi Manaer Tabusi Manaer Tabusi Manaer Jialehasibieke Sailike Xin Sun Baheban Yeerjiang Baheban Yeerjiang Baheban Yeerjiang Baheban Yeerjiang Xinhua Nabi Xinhua Nabi Xinhua Nabi Xinhua Nabi |
| author_sort | Tabusi Manaer |
| collection | DOAJ |
| description | BackgroundIn the Kazakh community of Xinjiang, China, fermented camel milk has been traditionally used to manage diabetes. This study evaluates the effects of composite probiotics derived from fermented camel milk (CPCM) on metabolic disturbances in a rat model of Type 2 diabetes (T2DM).MethodsT2DM was induced in Wistar rats using streptozotocin. Experimental groups included a diabetic control, Metformin, and low- and high-dose CPCM. Measurements over 6 weeks included body weight (BW), fasting blood glucose (FBG), oral glucose tolerance test (OGTT), glycated hemoglobin (HbA1c), C-peptide (CP), lipid profiles, inflammatory markers, fecal short-chain fatty acids (SCFAs), and tight junction protein expression in colonic tissues.ResultsHigh-dose CPCM significantly increased BW by 22.2% (p < 0.05) and reduced FBG by 6.5 mmol/L (p < 0.001). The OGTT AUC decreased by 40.1% (p < 0.001), and HbA1c levels fell by 22.9% (p < 0.01). CP levels rose by 21.8% (p < 0.05). Lipid profiles improved: TC decreased by 40.0%, TG by 17.1%, and LDL-C by 30.4% (all p < 0.001). Fecal SCFAs, including acetate (75.4%, p < 0.001), methyl acetate (18.9%, p < 0.05), and butyrate (289.9%, p < 0.001), increased, with total SCFAs rising by 89.7% (p < 0.001). Inflammatory markers IL-1β (12.7%, p < 0.01), TNF-α (16.7%, p < 0.05), and IL-6 (17.3%, p < 0.01) were significantly reduced. Tight junction protein expression (ZO-1, occludin, claudin-1) and mucin (MUC2) in colonic tissues increased (p < 0.05). CPCM treatment also reduced serum total bile acids by 24.9%, while hepatic and fecal bile acids increased by 114.0% and 37.8% (all p < 0.001). CPCM lowered serum DAO, D-lactate, and LPS levels (all p < 0.001). mRNA levels of TGR5 and CYP7A1 in the liver, and TGR5 and FXR in the colon, were markedly elevated (all p < 0.001). Histological examinations revealed reduced pancreatic inflammation and hepatic steatosis, with restored colonic structure.ConclusionCPCM treatment significantly improved metabolic dysregulation in the T2DM rat model, reducing blood glucose and lipid levels, enhancing intestinal barrier function, and increasing insulin secretion. These findings highlight the therapeutic potential of CPCM in T2DM management and probiotics’ role in metabolic health. |
| format | Article |
| id | doaj-art-514f96cad8be48adb270b8741c6375a2 |
| institution | Kabale University |
| issn | 1663-9812 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj-art-514f96cad8be48adb270b8741c6375a22025-01-07T06:40:49ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122025-01-011510.3389/fphar.2024.15201581520158Therapeutic effects of composite probiotics derived from fermented camel milk on metabolic dysregulation and intestinal barrier integrity in type 2 diabetes ratsTabusi Manaer0Tabusi Manaer1Tabusi Manaer2Tabusi Manaer3Jialehasibieke Sailike4Xin Sun5Baheban Yeerjiang6Baheban Yeerjiang7Baheban Yeerjiang8Baheban Yeerjiang9Xinhua Nabi10Xinhua Nabi11Xinhua Nabi12Xinhua Nabi13School of Pharmacy, Xinjiang Medical University, Urumchi, ChinaXinjiang Key Laboratory of Biopharmaceuticals and Medical Devices, Urumchi, ChinaXinjiang Key Laboratory of Natural Medicines Active Components and Drug Release Technology, Urumchi, ChinaEngineering Research Center of Xinjiang and Central Asian Medicine Resources, Ministry of Education, Urumchi, ChinaAffiliated Tumor Hospital, Xinjiang Medical University, Urumchi, ChinaSrational for Drug Control and Medical Device Varification of Xinjiang Military Command, Urumchi, ChinaSchool of Pharmacy, Xinjiang Medical University, Urumchi, ChinaXinjiang Key Laboratory of Biopharmaceuticals and Medical Devices, Urumchi, ChinaXinjiang Key Laboratory of Natural Medicines Active Components and Drug Release Technology, Urumchi, ChinaEngineering Research Center of Xinjiang and Central Asian Medicine Resources, Ministry of Education, Urumchi, ChinaSchool of Pharmacy, Xinjiang Medical University, Urumchi, ChinaXinjiang Key Laboratory of Biopharmaceuticals and Medical Devices, Urumchi, ChinaXinjiang Key Laboratory of Natural Medicines Active Components and Drug Release Technology, Urumchi, ChinaEngineering Research Center of Xinjiang and Central Asian Medicine Resources, Ministry of Education, Urumchi, ChinaBackgroundIn the Kazakh community of Xinjiang, China, fermented camel milk has been traditionally used to manage diabetes. This study evaluates the effects of composite probiotics derived from fermented camel milk (CPCM) on metabolic disturbances in a rat model of Type 2 diabetes (T2DM).MethodsT2DM was induced in Wistar rats using streptozotocin. Experimental groups included a diabetic control, Metformin, and low- and high-dose CPCM. Measurements over 6 weeks included body weight (BW), fasting blood glucose (FBG), oral glucose tolerance test (OGTT), glycated hemoglobin (HbA1c), C-peptide (CP), lipid profiles, inflammatory markers, fecal short-chain fatty acids (SCFAs), and tight junction protein expression in colonic tissues.ResultsHigh-dose CPCM significantly increased BW by 22.2% (p < 0.05) and reduced FBG by 6.5 mmol/L (p < 0.001). The OGTT AUC decreased by 40.1% (p < 0.001), and HbA1c levels fell by 22.9% (p < 0.01). CP levels rose by 21.8% (p < 0.05). Lipid profiles improved: TC decreased by 40.0%, TG by 17.1%, and LDL-C by 30.4% (all p < 0.001). Fecal SCFAs, including acetate (75.4%, p < 0.001), methyl acetate (18.9%, p < 0.05), and butyrate (289.9%, p < 0.001), increased, with total SCFAs rising by 89.7% (p < 0.001). Inflammatory markers IL-1β (12.7%, p < 0.01), TNF-α (16.7%, p < 0.05), and IL-6 (17.3%, p < 0.01) were significantly reduced. Tight junction protein expression (ZO-1, occludin, claudin-1) and mucin (MUC2) in colonic tissues increased (p < 0.05). CPCM treatment also reduced serum total bile acids by 24.9%, while hepatic and fecal bile acids increased by 114.0% and 37.8% (all p < 0.001). CPCM lowered serum DAO, D-lactate, and LPS levels (all p < 0.001). mRNA levels of TGR5 and CYP7A1 in the liver, and TGR5 and FXR in the colon, were markedly elevated (all p < 0.001). Histological examinations revealed reduced pancreatic inflammation and hepatic steatosis, with restored colonic structure.ConclusionCPCM treatment significantly improved metabolic dysregulation in the T2DM rat model, reducing blood glucose and lipid levels, enhancing intestinal barrier function, and increasing insulin secretion. These findings highlight the therapeutic potential of CPCM in T2DM management and probiotics’ role in metabolic health.https://www.frontiersin.org/articles/10.3389/fphar.2024.1520158/fullcolon healthcomposite probioticsfermented camel milklactic acid bacteriatight junction proteinstype 2 diabetes |
| spellingShingle | Tabusi Manaer Tabusi Manaer Tabusi Manaer Tabusi Manaer Jialehasibieke Sailike Xin Sun Baheban Yeerjiang Baheban Yeerjiang Baheban Yeerjiang Baheban Yeerjiang Xinhua Nabi Xinhua Nabi Xinhua Nabi Xinhua Nabi Therapeutic effects of composite probiotics derived from fermented camel milk on metabolic dysregulation and intestinal barrier integrity in type 2 diabetes rats Frontiers in Pharmacology colon health composite probiotics fermented camel milk lactic acid bacteria tight junction proteins type 2 diabetes |
| title | Therapeutic effects of composite probiotics derived from fermented camel milk on metabolic dysregulation and intestinal barrier integrity in type 2 diabetes rats |
| title_full | Therapeutic effects of composite probiotics derived from fermented camel milk on metabolic dysregulation and intestinal barrier integrity in type 2 diabetes rats |
| title_fullStr | Therapeutic effects of composite probiotics derived from fermented camel milk on metabolic dysregulation and intestinal barrier integrity in type 2 diabetes rats |
| title_full_unstemmed | Therapeutic effects of composite probiotics derived from fermented camel milk on metabolic dysregulation and intestinal barrier integrity in type 2 diabetes rats |
| title_short | Therapeutic effects of composite probiotics derived from fermented camel milk on metabolic dysregulation and intestinal barrier integrity in type 2 diabetes rats |
| title_sort | therapeutic effects of composite probiotics derived from fermented camel milk on metabolic dysregulation and intestinal barrier integrity in type 2 diabetes rats |
| topic | colon health composite probiotics fermented camel milk lactic acid bacteria tight junction proteins type 2 diabetes |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2024.1520158/full |
| work_keys_str_mv | AT tabusimanaer therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT tabusimanaer therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT tabusimanaer therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT tabusimanaer therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT jialehasibiekesailike therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT xinsun therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT bahebanyeerjiang therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT bahebanyeerjiang therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT bahebanyeerjiang therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT bahebanyeerjiang therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT xinhuanabi therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT xinhuanabi therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT xinhuanabi therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats AT xinhuanabi therapeuticeffectsofcompositeprobioticsderivedfromfermentedcamelmilkonmetabolicdysregulationandintestinalbarrierintegrityintype2diabetesrats |